Enterprise Value
846.2M
Cash
221.4M
Avg Qtr Burn
-14.06M
Short % of Float
0.25%
Insider Ownership
4.50%
Institutional Own.
83.80%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Apraglutide (agonist of the GLP-2 receptor) Details Acute graft-versus host disease | Phase 2 Interim update | |
Apraglutide (agonist of the GLP-2 receptor) Details Short bowel syndrome, Short bowel syndrome with colon-in-continuity | Phase 2 Update |